LeMaitre Vascular (LMAT) Competitors

Glaukos (NYSE:GKOS) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Which has higher valuation & earnings, GKOS or LMAT?

LeMaitre Vascular has lower revenue, but higher earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$404.52M	13.81	-$146.37M	-$2.37	-41.25
LeMaitre Vascular	$219.86M	8.20	$44.04M	$1.98	40.29

Is GKOS or LMAT more profitable?

LeMaitre Vascular has a net margin of 19.96% compared to Glaukos' net margin of -31.40%. LeMaitre Vascular's return on equity of 13.53% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-31.40%	-10.66%	-8.06%
LeMaitre Vascular	19.96%	13.53%	9.78%

Do insiders & institutionals believe in GKOS or LMAT?

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are owned by institutional investors. 5.8% of Glaukos shares are owned by company insiders. Comparatively, 9.5% of LeMaitre Vascular shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Do analysts recommend GKOS or LMAT?

Glaukos presently has a consensus price target of $134.67, indicating a potential upside of 37.75%. LeMaitre Vascular has a consensus price target of $97.83, indicating a potential upside of 22.64%. Given Glaukos' stronger consensus rating and higher probable upside, equities analysts plainly believe Glaukos is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
LeMaitre Vascular	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Which has more risk and volatility, GKOS or LMAT?

Glaukos has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.

Does the media favor GKOS or LMAT?

In the previous week, LeMaitre Vascular had 2 more articles in the media than Glaukos. MarketBeat recorded 7 mentions for LeMaitre Vascular and 5 mentions for Glaukos. LeMaitre Vascular's average media sentiment score of 1.37 beat Glaukos' score of 0.98 indicating that LeMaitre Vascular is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LeMaitre Vascular	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

LeMaitre Vascular beats Glaukos on 9 of the 15 factors compared between the two stocks.